Next Article in Journal
Usefulness of the Waist Circumference-to-Height Ratio in Screening for Obesity and Metabolic Syndrome among Korean Children and Adolescents: Korea National Health and Nutrition Examination Survey, 2010–2014
Previous Article in Journal
Iodine and Selenium Intakes of Postmenopausal Women in New Zealand
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessArticle
Nutrients 2017, 9(3), 255;

Effects of Resveratrol Supplementation on  Methotrexate Chemotherapy‐Induced Bone Loss

Sansom Institute for Health Research, School of Pharmacy and Medical Sciences, University of South Australia, Adelaide SA 5001, Australia
Institute of Orthopaedics, Lanzhou General Hospital, Lanzhou Command of People’s Liberation Army, Lanzhou 730050, China
Clinical Nutrition Research Centre, University of Newcastle, Callaghan NSW 2308, Australia
Author to whom correspondence should be addressed.
Received: 16 February 2017 / Accepted: 8 March 2017 / Published: 9 March 2017
Full-Text   |   PDF [6162 KB, uploaded 10 March 2017]   |  


Intensive cancer chemotherapy is known to cause bone defects, which currently lack treatments. This study investigated the effects of polyphenol resveratrol (RES) in preventing bone defects in rats caused by methotrexate (MTX), a commonly used antimetabolite in childhood oncology. Young rats received five daily MTX injections at 0.75 mg/kg/day. RES was orally gavaged daily for seven days prior to, and during, five‐day MTX administration. MTX reduced growth plate thickness, primary spongiosa height, trabecular bone volume, increased marrow adipocyte density, and increased mRNA expression of the osteogenic, adipogenic, and osteoclastogenic factors in the tibial bone. RES at 10 mg/kg was found not to affect bone health in normal rats, but to aggravate the bone damage in MTX‐treated rats. However, RES supplementation at 1 mg/kg preserved the growth plate, primary spongiosa, bone volume, and lowered the adipocyte density. It maintained expression of genes involved in osteogenesis and decreased expression of adipogenic and osteoclastogenic factors. RES suppressed osteoclast formation ex vivo of bone marrow cells from the treated rats. These data suggest that MTX can enhance osteoclast and adipocyte formation and cause bone loss, and that RES supplementation at 1 mg/kg may potentially prevent these bone defects. View Full-Text
Keywords: resveratrol; cancer chemotherapy; methotrexate; bone loss; bone marrow adiposity;  bone growth arrest; growth plate; osteoclasts; osteoblasts; adipocytes resveratrol; cancer chemotherapy; methotrexate; bone loss; bone marrow adiposity;  bone growth arrest; growth plate; osteoclasts; osteoblasts; adipocytes

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Lee, A.M.C.; Shandala, T.; Soo, P.P.; Su, Y.; King, T.J.; Chen, K.; Howe, P.R.; Xian, C.J. Effects of Resveratrol Supplementation on  Methotrexate Chemotherapy‐Induced Bone Loss. Nutrients 2017, 9, 255.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Nutrients EISSN 2072-6643 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top